Selected research
Industry Research
Topical Thrombin Industry Research Report 2026
Market perspective
The global Topical Thrombin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Topical Thrombin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Topical Thrombin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Topical Thrombin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Topical Thrombin include Takeda, Shanghai RAAS, Pfizer, Hualan Biological, Bayer, Omrix Biopharmaceuticals, Octapharma, Haematologic Technologies and Grifols, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Topical Thrombin market in terms of revenue (US$ million) and, where applicable, sales volume (tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Topical Thrombin Market by Company
Takeda
Shanghai RAAS
Pfizer
Hualan Biological
Bayer
Omrix Biopharmaceuticals
Octapharma
Haematologic Technologies
Grifols
GE Healthcare
CSL
Topical Thrombin Segment by Type
Based Bovine
Based Human
Others
Topical Thrombin Segment by Application
Academic and Research Institute
Hospitals
Diagnostics & Clinics
Topical Thrombin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topical Thrombin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Topical Thrombin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topical Thrombin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Topical Thrombin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Topical Thrombin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Topical Thrombin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Based Bovine
- Based Human
- Others
Applications
- Academic and Research Institute
- Hospitals
- Diagnostics & Clinics
Companies covered
- Takeda
- Shanghai RAAS
- Pfizer
- Hualan Biological
- Bayer
- Omrix Biopharmaceuticals
- Octapharma
- Haematologic Technologies
- Grifols
- GE Healthcare
- CSL
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Topical Thrombin Market Size (2021-2032)
- 2.2.2 Global Topical Thrombin Sales (2021-2032)
- 2.2.3 Global Topical Thrombin Market Average Price (2021-2032)
- 2.3 Topical Thrombin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Based Bovine
- 2.3.3 Based Human
- 2.3.4 Others
- 2.4 Topical Thrombin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Academic and Research Institute
- 2.4.3 Hospitals
- 2.4.4 Diagnostics & Clinics
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Topical Thrombin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Topical Thrombin Sales (tons) of Manufacturers (2021-2026)
- 3.3 Global Topical Thrombin Revenue of Manufacturers (2021-2026)
- 3.4 Global Topical Thrombin Average Price by Manufacturers (2021-2026)
- 3.5 Global Topical Thrombin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Topical Thrombin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Topical Thrombin, Product Type & Application
- 3.8 Global Manufacturers of Topical Thrombin, Established Date
- 3.9 Global Topical Thrombin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Topical Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Topical Thrombin Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Shanghai RAAS
- 4.2.1 Shanghai RAAS Company Information
- 4.2.2 Shanghai RAAS Business Overview
- 4.2.3 Shanghai RAAS Topical Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shanghai RAAS Topical Thrombin Product Portfolio
- 4.2.5 Shanghai RAAS Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Topical Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Topical Thrombin Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Hualan Biological
- 4.4.1 Hualan Biological Company Information
- 4.4.2 Hualan Biological Business Overview
- 4.4.3 Hualan Biological Topical Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hualan Biological Topical Thrombin Product Portfolio
- 4.4.5 Hualan Biological Recent Developments
- 4.5 Bayer
- 4.5.1 Bayer Company Information
- 4.5.2 Bayer Business Overview
- 4.5.3 Bayer Topical Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bayer Topical Thrombin Product Portfolio
- 4.5.5 Bayer Recent Developments
- 4.6 Omrix Biopharmaceuticals
- 4.6.1 Omrix Biopharmaceuticals Company Information
- 4.6.2 Omrix Biopharmaceuticals Business Overview
- 4.6.3 Omrix Biopharmaceuticals Topical Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Omrix Biopharmaceuticals Topical Thrombin Product Portfolio
- 4.6.5 Omrix Biopharmaceuticals Recent Developments
- 4.7 Octapharma
- 4.7.1 Octapharma Company Information
- 4.7.2 Octapharma Business Overview
- 4.7.3 Octapharma Topical Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Octapharma Topical Thrombin Product Portfolio
- 4.7.5 Octapharma Recent Developments
- 4.8 Haematologic Technologies
- 4.8.1 Haematologic Technologies Company Information
- 4.8.2 Haematologic Technologies Business Overview
- 4.8.3 Haematologic Technologies Topical Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Haematologic Technologies Topical Thrombin Product Portfolio
- 4.8.5 Haematologic Technologies Recent Developments
- 4.9 Grifols
- 4.9.1 Grifols Company Information
- 4.9.2 Grifols Business Overview
- 4.9.3 Grifols Topical Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Grifols Topical Thrombin Product Portfolio
- 4.9.5 Grifols Recent Developments
- 4.10 GE Healthcare
- 4.10.1 GE Healthcare Company Information
- 4.10.2 GE Healthcare Business Overview
- 4.10.3 GE Healthcare Topical Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 GE Healthcare Topical Thrombin Product Portfolio
- 4.10.5 GE Healthcare Recent Developments
- 4.11 CSL
- 4.11.1 CSL Company Information
- 4.11.2 CSL Business Overview
- 4.11.3 CSL Topical Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 CSL Topical Thrombin Product Portfolio
- 4.11.5 CSL Recent Developments
5 Global Topical Thrombin Market Scenario by Region
- 5.1 Global Topical Thrombin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Topical Thrombin Sales by Region: 2021-2032
- 5.2.1 Global Topical Thrombin Sales by Region: 2021-2026
- 5.2.2 Global Topical Thrombin Sales by Region: 2027-2032
- 5.3 Global Topical Thrombin Revenue by Region: 2021-2032
- 5.3.1 Global Topical Thrombin Revenue by Region: 2021-2026
- 5.3.2 Global Topical Thrombin Revenue by Region: 2027-2032
- 5.4 North America Topical Thrombin Market Facts & Figures by Country
- 5.4.1 North America Topical Thrombin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Topical Thrombin Sales by Country (2021-2032)
- 5.4.3 North America Topical Thrombin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Topical Thrombin Market Facts & Figures by Country
- 5.5.1 Europe Topical Thrombin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Topical Thrombin Sales by Country (2021-2032)
- 5.5.3 Europe Topical Thrombin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Topical Thrombin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Topical Thrombin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Topical Thrombin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Topical Thrombin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Topical Thrombin Market Facts & Figures by Country
- 5.7.1 South America Topical Thrombin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Topical Thrombin Sales by Country (2021-2032)
- 5.7.3 South America Topical Thrombin Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Topical Thrombin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Topical Thrombin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Topical Thrombin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Topical Thrombin Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Topical Thrombin Sales by Type (2021-2032)
- 6.1.1 Global Topical Thrombin Sales by Type (2021-2032) & (tons)
- 6.1.2 Global Topical Thrombin Sales Market Share by Type (2021-2032)
- 6.2 Global Topical Thrombin Revenue by Type (2021-2032)
- 6.2.1 Global Topical Thrombin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Topical Thrombin Revenue Market Share by Type (2021-2032)
- 6.3 Global Topical Thrombin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Topical Thrombin Sales by Application (2021-2032)
- 7.1.1 Global Topical Thrombin Sales by Application (2021-2032) & (tons)
- 7.1.2 Global Topical Thrombin Sales Market Share by Application (2021-2032)
- 7.2 Global Topical Thrombin Revenue by Application (2021-2032)
- 7.2.1 Global Topical Thrombin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Topical Thrombin Revenue Market Share by Application (2021-2032)
- 7.3 Global Topical Thrombin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Topical Thrombin Value Chain Analysis
- 8.1.1 Topical Thrombin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Topical Thrombin Production Mode & Process
- 8.2 Topical Thrombin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Topical Thrombin Distributors
- 8.2.3 Topical Thrombin Customers
9 Global Topical Thrombin Analyzing Market Dynamics
- 9.1 Topical Thrombin Industry Trends
- 9.2 Topical Thrombin Industry Drivers
- 9.3 Topical Thrombin Industry Opportunities and Challenges
- 9.4 Topical Thrombin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst